BioCryst Pharmaceuticals (BCRX) Stock Forecast for 2023 – 2026. Sell or Buy?
Updated: December 3, 2023 (06:41)
Sector: HealthcareThe share price of BioCryst Pharmaceuticals, Inc. (BCRX) now
50/200 Day Moving Average: $6.08 / $7.47
This figure corresponds to the Average Price over the previous 50/200 days. For BioCryst Pharmaceuticals stocks, the 50-day moving average is the support level today.
For BioCryst Pharmaceuticals stocks, the 200-day moving average is the resistance level today.
Are you interested in BioCryst Pharmaceuticals, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the BioCryst Pharmaceuticals stock price in 2023, 2024, 2025, 2026, 2027. How much will one BioCryst Pharmaceuticals share be worth in 2023 - 2027?
When should I take profit in BioCryst Pharmaceuticals stock? When should I record a loss on BioCryst Pharmaceuticals stock? What are analysts' forecasts for BioCryst Pharmaceuticals stock? What is the future of BioCryst Pharmaceuticals stock? We forecast BioCryst Pharmaceuticals stock performance using neural networks based on historical data on BioCryst Pharmaceuticals stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
BioCryst Pharmaceuticals stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2023, 2024, 2025, 2026 and 2027) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for BioCryst Pharmaceuticals shares. This happens once a day.
Historical and forecast chart of BioCryst Pharmaceuticals stock
The chart below shows the historical price of BioCryst Pharmaceuticals stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the BioCryst Pharmaceuticals stock price can be found in the table below.
Long-term forecasts by years.
BioCryst Pharmaceuticals, Inc., a biotech company, is dedicated to the discovery of oral and small molecule drugs. The company markets injections of peramivir, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza, under the names RAPIVAB, ALPIVAB, RAPIACTA and PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for the treatment of peripheral T-cell lymphoma.
BioCryst Pharmaceuticals daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec 05 | 6.19 | 6.04 | 6.24 | 3.35 |
| Dec 06 | 6.20 | 6.05 | 6.31 | 4.29 |
| Dec 07 | 6.27 | 6.13 | 6.38 | 3.99 |
| Dec 08 | 6.23 | 6.11 | 6.29 | 2.97 |
| Dec 09 | 6.20 | 6.15 | 6.26 | 1.71 |
| Dec 10 | 6.22 | 6.09 | 6.38 | 4.77 |
| Dec 11 | 6.23 | 6.19 | 6.38 | 3.03 |
| Dec 12 | 6.25 | 6.18 | 6.29 | 1.65 |
| Dec 13 | 6.27 | 6.20 | 6.31 | 1.81 |
| Dec 14 | 6.17 | 6.04 | 6.23 | 3.11 |
| Dec 15 | 6.11 | 5.98 | 6.20 | 3.73 |
| Dec 16 | 6.28 | 6.18 | 6.35 | 2.70 |
| Dec 17 | 6.46 | 6.42 | 6.50 | 1.29 |
| Dec 18 | 6.63 | 6.58 | 6.68 | 1.45 |
| Dec 19 | 6.74 | 6.64 | 6.82 | 2.76 |
| Dec 20 | 6.79 | 6.69 | 6.84 | 2.17 |
| Dec 21 | 6.89 | 6.79 | 6.99 | 2.92 |
| Dec 22 | 7.01 | 6.94 | 7.12 | 2.58 |
| Dec 23 | 7.02 | 6.87 | 7.12 | 3.73 |
| Dec 24 | 6.80 | 6.75 | 6.97 | 3.26 |
| Dec 25 | 6.76 | 6.60 | 6.82 | 3.34 |
| Dec 26 | 6.83 | 6.69 | 6.98 | 4.41 |
| Dec 27 | 6.91 | 6.81 | 7.03 | 3.25 |
| Dec 28 | 6.95 | 6.91 | 7.03 | 1.77 |
| Dec 29 | 7.12 | 6.98 | 7.21 | 3.36 |
| Dec 30 | 7.15 | 7.03 | 7.28 | 3.54 |
| Dec 31 | 7.04 | 6.91 | 7.18 | 3.91 |
| Jan 01 | 7.08 | 7.00 | 7.14 | 2.07 |
| Jan 02 | 6.92 | 6.76 | 6.99 | 3.41 |
| Jan 03 | 6.82 | 6.66 | 6.92 | 3.94 |
BioCryst Pharmaceuticals Daily Price Targets
BioCryst Pharmaceuticals Stock Forecast 12-05-2023.
Forecast target price for 12-05-2023: $6.19.
Positive dynamics for BioCryst Pharmaceuticals shares will prevail with possible volatility of 3.240%.
Pessimistic target level: 6.04
Optimistic target level: 6.24
BioCryst Pharmaceuticals Stock Forecast 12-06-2023.
Forecast target price for 12-06-2023: $6.20.
Positive dynamics for BioCryst Pharmaceuticals shares will prevail with possible volatility of 4.117%.
Pessimistic target level: 6.05
Optimistic target level: 6.31
BioCryst Pharmaceuticals Stock Forecast 12-07-2023.
Forecast target price for 12-07-2023: $6.27.
Positive dynamics for BioCryst Pharmaceuticals shares will prevail with possible volatility of 3.837%.
Pessimistic target level: 6.13
Optimistic target level: 6.38
BioCryst Pharmaceuticals Stock Forecast 12-08-2023.
Forecast target price for 12-08-2023: $6.23.
Negative dynamics for BioCryst Pharmaceuticals shares will prevail with possible volatility of 2.882%.
Pessimistic target level: 6.11
Optimistic target level: 6.29
BioCryst Pharmaceuticals Stock Forecast 12-09-2023.
Forecast target price for 12-09-2023: $6.20.
Negative dynamics for BioCryst Pharmaceuticals shares will prevail with possible volatility of 1.681%.
Pessimistic target level: 6.15
Optimistic target level: 6.26
BioCryst Pharmaceuticals Stock Forecast 12-10-2023.
Forecast target price for 12-10-2023: $6.22.
Positive dynamics for BioCryst Pharmaceuticals shares will prevail with possible volatility of 4.557%.
Pessimistic target level: 6.09
Optimistic target level: 6.38
BCRX (BCRX) Monthly Stock Prediction for 2023
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec. | 5.66 | 5.38 | 5.94 | 9.39 |
BioCryst Pharmaceuticals forecast for this year
BioCryst Pharmaceuticals Stock Prediction for Dec 2023
An downtrend is forecast for this month with an optimal target price of $5.66474. Pessimistic: $5.38. Optimistic: $5.94
BioCryst Pharmaceuticals (BCRX) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 5.48 | 5.15 | 5.93 | 13.09 |
| Feb | 5.26 | 5.06 | 5.70 | 11.18 |
| Mar | 5.26 | 5.07 | 5.56 | 8.85 |
| Apr | 5.10 | 4.87 | 5.55 | 12.25 |
| May | 4.90 | 4.76 | 5.11 | 6.79 |
| Jun | 4.99 | 4.84 | 5.47 | 11.61 |
| Jul | 4.79 | 4.58 | 5.07 | 9.63 |
| Aug | 4.82 | 4.41 | 5.19 | 15.06 |
| Sep | 4.92 | 4.80 | 5.08 | 5.57 |
| Oct | 4.76 | 4.59 | 5.16 | 10.97 |
| Nov | 4.31 | 3.93 | 4.44 | 11.53 |
| Dec | 4.37 | 3.96 | 4.50 | 11.90 |
BioCryst Pharmaceuticals (BCRX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 4.38 | 3.99 | 4.49 | 11.11 |
| Feb | 4.77 | 4.38 | 5.07 | 13.55 |
| Mar | 4.49 | 4.10 | 4.66 | 11.90 |
| Apr | 4.44 | 4.28 | 4.55 | 5.96 |
| May | 4.59 | 4.40 | 4.81 | 8.46 |
| Jun | 4.97 | 4.80 | 5.35 | 10.25 |
| Jul | 5.09 | 4.97 | 5.39 | 7.82 |
| Aug | 4.88 | 4.44 | 5.14 | 13.55 |
| Sep | 4.60 | 4.16 | 4.72 | 11.91 |
| Oct | 4.54 | 4.15 | 4.96 | 16.26 |
| Nov | 5.09 | 4.76 | 5.31 | 10.34 |
| Dec | 5.67 | 5.53 | 5.99 | 7.61 |
BioCryst Pharmaceuticals (BCRX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 5.52 | 5.17 | 5.99 | 13.70 |
| Feb | 5.89 | 5.71 | 6.31 | 9.53 |
| Mar | 6.01 | 5.52 | 6.32 | 12.67 |
| Apr | 5.62 | 5.39 | 6.09 | 11.53 |
| May | 5.24 | 5.07 | 5.68 | 10.74 |
| Jun | 4.75 | 4.52 | 4.90 | 7.90 |
| Jul | 5.03 | 4.88 | 5.50 | 11.19 |
| Aug | 5.08 | 4.76 | 5.51 | 13.60 |
| Sep | 5.59 | 5.15 | 5.91 | 12.82 |
| Oct | 5.56 | 5.33 | 5.74 | 7.10 |
| Nov | 6.15 | 5.74 | 6.33 | 9.44 |
| Dec | 6.33 | 5.73 | 6.59 | 13.14 |
BioCryst Pharmaceuticals (BCRX) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 6.05 | 5.78 | 6.41 | 9.86 |
| Feb | 6.66 | 6.43 | 7.04 | 8.63 |
| Mar | 6.07 | 5.63 | 6.38 | 11.87 |
| Apr | 6.03 | 5.56 | 6.33 | 12.24 |
| May | 6.33 | 5.73 | 6.66 | 13.92 |
| Jun | 6.18 | 5.69 | 6.48 | 12.24 |
| Jul | 6.87 | 6.25 | 7.12 | 12.16 |
| Aug | 6.50 | 6.01 | 6.94 | 13.37 |
| Sep | 6.29 | 5.99 | 6.66 | 9.97 |
| Oct | 6.12 | 5.67 | 6.34 | 10.54 |
| Nov | 6.31 | 5.93 | 6.80 | 12.80 |
| Dec | 6.58 | 6.40 | 7.22 | 11.28 |
BioCryst Pharmaceuticals information and performance
4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, US
Market capitalization of the BioCryst Pharmaceuticals, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of BCRX shares in the company outstanding by the market price of one share.
EBITDA of BioCryst Pharmaceuticals is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
